DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l2dc45/cough_pipeline) has announced the addition of the "Cough - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Afferent Pharmaceuticals, Inc.
- Ahn-Gook Pharmaceutical Co., Ltd.
- Alitair Pharmaceuticals, Inc.
- Ario Pharma Ltd
- AstraZeneca Plc
- AUS Bio Limited
- Conrig Pharma ApS
- Daewoong Pharmaceutical Co., Ltd.
- Glenmark Pharmaceuticals Ltd.
- Hydra Biosciences, Inc.
- Hyundai Pharmaceutical Co., Ltd.
- Infirst Healthcare Limited
- Johnson & Johnson
- Neos Therapeutics, Inc.
- NeRRe Therapeutics Ltd
- Orbis Biosciences, Inc.
- Patara Pharma, Inc.
- Vernalis Plc
Drug Profiles
- AF-219
- AG-1321001
- AG-1321001-SY
- AGPPC-709
- benzonatate polacrilex
- CCP-05
- CCP-06
- CCP-07
- CCP-08
- codeine + guaifenesin
- cromolyn sodium
- CS-1002
- DWJ-1340
- GRC-17536
- guaifenesin + hydrocodone
- guaifenesin ER
- HC-030031
- JNJ-39729209
- lesogaberan
- levodropropizine
- MD-990
- orvepitant maleate
- Small Molecule for Cough and Cold
- Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders
- ST-015
- XEND-0501
For more information visit http://www.researchandmarkets.com/research/l2dc45/cough_pipeline
